New ADC manufacturing suite complements existing GMP capability to support partner companies through development and manufacturing.
In an effort to significantly expand the group’s integrated ADC chemistry solutions, Abzena has completed the remodeling of its new antibody-drug conjugate (ADC) GMP manufacturing suite at its site in Bristol, Pennsylvania. The verification and qualification of the facility and equipment is scheduled for completion at the end of the second quarter of 2018: “The combination of state-of-the-art facilities, solutions and leading technologies will enable Abzena to support its international customers as they progress their drug development programs from research into clinical trials,” said Sanjeevani Ghone, vice president and site head of Abzena, Bristol.
The new suite will be outfitted with state-of-the-art Sartorius and GE single-use equipment for scale-up, manufacture and purification processes. Head of global marketing, Min Park, added that this new capability will help Abzena support partner companies through the development and manufacturing continuum to ADC drug substance within one company. In addition, the company also plans on upgrading its biologics process development and manufacturing capabilities at a new facility in San Diego. Relocation to the new facility is expected during April 2018.
